

Investor Information Sheet

Company Name:	CamRegen Limited
Funding Stage:	Seed
Investment Opportunity:	£3.2 million for a 30 month runway
Web address	www.camregen.com



Bringing a step change improvement in clinical outcomes by redefining tissue repair technologies

CamRegen is a deep science regenerative technology company spun out from the University of Cambridge's Department of Materials Science seeking to improve surgical outcomes by redefining tissue repair technologies.

The Challenge: CamRegen's unique and proprietary technology platform addresses the need for improved dura implants in brain neurosurgeries, a market of ca \$2.5 billion with a known problem of product failure leading to post-surgical complications in patients, poor clinical outcomes and a healthcare cost burden of hundreds of millions of USD.


The Solution: The technology is a novel fabrication platform based on Electrophoretic Deposition (EPD) whose USP lies in the ability to make implants and devices from biomaterials with improved properties tailored for individual clinical applications.

The first commercial application of a dura substitute implant will address the performance gaps in current products by providing neurosurgeons with an 'all-in-one' solution, currently not available, that has

- High strength to allow easier handling and higher product integrity
- Ability to form a good seal on the native dura to prevent CSF leaks
- Non sticky surfaces to prevent adherence to brain tissues

CamRegen's dura substitute implant will have a direct and positive impact on the patient experience and clinical outcomes in neurosurgeries by radically reducing post-surgery product failure rate.

Milestones to date



2021

- CamRegen incorporated
- CE Pathfinder Convertible Loan ca £11,500 for market research to confirm clinical application area
- Technology's Proof of Concept demonstrated to Technology Readiness Level 3
- Accepted into the prestigious Accelerate @ Babraham incubator programme, with a cash award of £10,000 and access to shared lab and office facilities at the Babraham Research Campus
- Convertible Loan of £75,000 from Cambridge Enterprise Seed Funds

2022

- CPI Regulatory grant of £30,000 for expert review of the regulatory pathway for UK, EU and US
- Small Animal safety study that has demonstrated no safety issues of the EPD technology compared to existing methods for collagen fabrication

Investor Information Sheet

Funding Opportunity

CamRegen is currently seeking a seed investment of ca £3.2 million to see completion of the following milestones ahead of a Series A round

- Product development with design freeze and process parameters locked down
- Safety, biocompatibility and efficacy tests for the final product design in compliance with medical device regulatory standards
- Validated Packaging and Sterilisation processes for the product
- A fully implemented Quality Management System (QMS) with ISO13485 certification
- Submission of US FDA 510(k) application
- Recruitment of a core team to drive forward the product development and regulatory compliance activities

Management Team

Dr Siddhartha Ghose, CEO

Siddhartha Ghose has over 12 years of senior management experience in early and growth stage UK life-science, medical technology and healthcare start-ups including OrthoMimetics, TiGenix, EnXray and Fluidic Analytics where he held a variety of roles including business planning and fund-raising, R&D and commercial project management, product development and innovation management.



Dr David Barrett, CTO

David Barrett is a co-founder and co-inventor of the key technologies underpinning the CamRegen and has over 8 years of experience working with collagen and electrophoretic deposition.



References & Patents:

CamRegen's has a filed patent application (WO2019219916A2, priority date in May 2018) that is currently in national phases in Europe, US and Japan.

The patent relates to fabrication of collagen biomaterials using Electrophoretic Deposition. CamRegen is negotiating an exclusive worldwide royalty-based licence from Cambridge Enterprise for clinical and non-clinical applications.

For further information please contact:

Fatima Kranc
Investment Manager

Fatima.kranc@enterprise.cam.ac.uk
www.enterprise.cam.ac.uk

